Join
Live feed
·
PRReleasevia Quantisnow
Cybin Inc. logo

Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

ByQuantisnow·Wall Street's wire, on your screen.
CYBN· Cybin Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CYBN (Cybin Inc.) and more on Quantisnow.